miércoles, 17 de mayo de 2017

Journal for ImmunoTherapy of Cancer | Reviews

Journal for ImmunoTherapy of Cancer | Reviews

Biomed Central

Journal for ImmunoTherapy of Cancer

JITC logo

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)


Section edited by Thomas F. Gajewski, MD, PhD and Per Thor Straten, PhD
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.


    Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

    As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...
    Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton and Lisa H. Butterfield
    Journal for ImmunoTherapy of Cancer 2017 5:44
    Published on: 16 May 2017

    Systematic evaluation of immune regulation and modulation

    Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...
    David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger
    Journal for ImmunoTherapy of Cancer 2017 5:21
    Published on: 21 March 2017

    Combination immunotherapy: a road map

    Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...
    Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok
    Journal for ImmunoTherapy of Cancer 2017 5:16
    Published on: 21 February 2017

    A New VISTA on combination therapy for negative checkpoint regulator blockade

    Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-med...
    Jie Deng, Isabelle Le Mercier, Anna Kuta and Randolph J. Noelle
    Journal for ImmunoTherapy of Cancer 2016 4:86
    Published on: 20 December 2016

    Canine cancer immunotherapy studies: linking mouse and human

    Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populatio...
    Jiwon S. Park, Sita S. Withers, Jaime F. Modiano, Michael S. Kent, Mingyi Chen, Jesus I. Luna, William T. N. Culp, Ellen E. Sparger, Robert B. Rebhun, Arta M. Monjazeb, William J. Murphy and Robert J. Canter
    Journal for ImmunoTherapy of Cancer 2016 4:97
    Published on: 20 December 2016

    Adjuvants for peptide-based cancer vaccines

    Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolo...
    Hiep Khong and Willem W. Overwijk
    Journal for ImmunoTherapy of Cancer 2016 4:56
    Published on: 20 September 2016

    B cell regulation of the anti-tumor response and role in carcinogenesis

    The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to cali...
    Marc Schwartz, Yu Zhang and Joseph D. Rosenblatt
    Journal for ImmunoTherapy of Cancer 2016 4:40
    Published on: 19 July 2016

    What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO)

    Treatment strategies that target the immune system provide the opportunity for antitumor activity across multiple cancer types, regardless of mutational status or tumor histology. While many of the initial adv...
    Paolo Antonio Ascierto, Giacomo Cartenì, Cesare Gridelli, Sandro Pignata, Antonio Pinto, Carmen Criscitiello, Luigi Buonaguro, Stefano Pepe, Roberto Mabilia, Vincenzo Montesarchio, Bruno Daniele and Sabino De Placido
    Journal for ImmunoTherapy of Cancer 2016 4:41
    Published on: 19 July 2016

    Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically t...
    Holbrook E. Kohrt, Paul C. Tumeh, Don Benson, Nina Bhardwaj, Joshua Brody, Silvia Formenti, Bernard A. Fox, Jerome Galon, Carl H. June, Michael Kalos, Ilan Kirsch, Thomas Kleen, Guido Kroemer, Lewis Lanier, Ron Levy, H. Kim Lyerly…
    Journal for ImmunoTherapy of Cancer 2016 4:15
    Published on: 15 March 2016

    The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer

    In this paper, we review recent advances in immuno-oncology with particular focus on liver, kidney, and bladder cancers as discussed at the 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO).
    Bruno Daniele, Bruno Sangro, Daniel Petrylak, Fabio Calabrò, Giacomo Cartenì, Vincenzo Montesarchio, Sabino De Placido and Paolo A. Ascierto
    Journal for ImmunoTherapy of Cancer 2016 4:1
    Published on: 19 January 2016
  11. REVIEW

    Novel technologies and emerging biomarkers for personalized cancer immunotherapy

    The culmination of over a century’s work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses i...
    Jianda Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C. Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao…
    Journal for ImmunoTherapy of Cancer 2016 4:3
    Published on: 19 January 2016
  12. REVIEW

    Targeting the indoleamine 2,3-dioxygenase pathway in cancer

    Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. ...
    Yong Wha Moon, Joud Hajjar, Patrick Hwu and Aung Naing
    Journal for ImmunoTherapy of Cancer 2015 3:51
    Published on: 15 December 2015

    Combination immunotherapy: Where do we go from here?

    The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. ...
    Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson and Dario A. A. Vignali
    Journal for ImmunoTherapy of Cancer 2015 3:38
    Published on: 18 August 2015
  14. REVIEW


    The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently...
    Leila Khoja, Marcus O. Butler, S. Peter Kang, Scot Ebbinghaus and Anthony M. Joshua
    Journal for ImmunoTherapy of Cancer 2015 3:36
    Published on: 18 August 2015

No hay comentarios:

Publicar un comentario